Búsqueda | BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas

1.

Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study.

Scagliotti, G V; Kosmidis, P; de Marinis, F; Schreurs, A J M; Albert, I; Engel-Riedel, W; Schallier, D; Barbera, S; Kuo, H-P; Sallo, V; Perez, J R; Manegold, C.

Ann Oncol ; 23(8): 2082-2087, 2012 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-22730101

2.

Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial.

Gridelli, C; Manegold, C; Mali, P; Reck, M; Portalone, L; Castelnau, O; Stahel, R; Betticher, D; Pless, M; Pons, J Terrassa; Aubert, D; Burillon, J-P; Parlier, Y; De Marinis, F.

Eur J Cancer ; 40(16): 2424-31, 2004 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-15519515

3.

Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: an international update.

Kris, M G; Manegold, C.

Semin Oncol ; 28(1 Suppl 2): 1-3, 2001 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-11284618

4.

Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.

Georgoulias, V; Scagliotti, G; Miller, V; Eckardt, J; Douillard, J Y; Manegold, C.

Semin Oncol ; 28(1 Suppl 2): 15-21, 2001 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-11284620

5.

Chemotherapy for advanced non-small cell lung cancer: standards.

Manegold, C.

Lung Cancer ; 34 Suppl 2: S165-70, 2001 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-11720760

6.

Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.

Braybrooke, J P; Ranson, M; Manegold, C; Mattson, K; Thatcher, N; Cheverton, P; Sekiguchi, M; Suzuki, M; Oyama, R; Talbot, D C.

Lung Cancer ; 41(2): 215-9, 2003 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-12871785

7.

[Docetaxel (taxotere) in non-small-cell bronchial carcinoma]. / Docetaxel (Taxotere) beim nichtkleinzelligen Bronchialkarzinom.

Manegold, C.

Med Klin (Munich) ; 92 Suppl 4: 10-5, 1997 Sep 15.

Artículo en Alemán | MEDLINE | ID: mdl-9446014

8.

[Docetaxel (taxotere): current status of clinical development in non-small-cell bronchial carcinoma (NSCLC)]. / Docetaxel (Taxotere): Aktueller Stand der klinischen Entwicklung beim nichtkleinzelligen Bronchialkarzinom (NSCLC).

Manegold, C.

Med Klin (Munich) ; 93 Suppl 3: 16-21, 1998 Sep 15.

Artículo en Alemán | MEDLINE | ID: mdl-9796220

9.

[Docetaxel (Taxotere) as first-line therapy of advanced non-small cell lung cancer (NSCLC)]. / Docetaxel (Taxotere) in der First-line-Therapie des fortgeschrittenen nicht-kleinzelligen Bronchialkarzinoms (NSCLC).

Manegold, C.

Onkologie ; 26 Suppl 7: 26-32, 2003 Dec.

Artículo en Alemán | MEDLINE | ID: mdl-14716139

BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas - MTCI

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study.

Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial.

Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: an international update.

Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.

Chemotherapy for advanced non-small cell lung cancer: standards.

Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.

[Docetaxel (taxotere) in non-small-cell bronchial carcinoma]. / Docetaxel (Taxotere) beim nichtkleinzelligen Bronchialkarzinom.

[Docetaxel (taxotere): current status of clinical development in non-small-cell bronchial carcinoma (NSCLC)]. / Docetaxel (Taxotere): Aktueller Stand der klinischen Entwicklung beim nichtkleinzelligen Bronchialkarzinom (NSCLC).

[Docetaxel (Taxotere) as first-line therapy of advanced non-small cell lung cancer (NSCLC)]. / Docetaxel (Taxotere) in der First-line-Therapie des fortgeschrittenen nicht-kleinzelligen Bronchialkarzinoms (NSCLC).